• 12/22/2005
  • Piscataway, NJ
  • press release
  • NPI Center (www.npicenter.com)

Sabinsa Corporation’s Curcumin C3 Complex(R) was named as the curcumin ingredient of choice by M.D. Anderson Cancer Center at the University of Texas. M.D. Anderson Cancer Center is currently conducting numerous studies to determine the effects of curcumin, an extract of turmeric root, in fighting against several types of cancers.

“Although there are numerous companies that supply curcumin, consumers need to be careful that they are buying the genuine product, which is why we recommend Sabinsa Corporation,” stated Dr. Bharat Aggarwal, professor of cancer research, M.D. Anderson Cancer Center. “A ‘supercurcumin’ is also available from Sabinsa that contains Bioperine(R), a standardized pepper extract, which enhances curcumin’s effectiveness.”

According to researchers at M.D. Anderson Cancer Center, curcumin blocks a key biological pathway needed for development of melanoma and other cancers. Curcumin shuts down nuclear factor-kappa B (NF-kB), a powerful master switch known to regulate expression of more than 300 genes that promote an abnormal inflammatory response that leads to a variety of disorders, including arthritis and cancer.

“We strive to provide safe and effective standardized ingredients of the highest quality to our customers around the world. It is gratifying to see the growing interest in research involving our patented Curcumin C3 Complex,” stated Todd Norton, president, Sabinsa Corporation.

Curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin are collectively known as curcuminoids, and are recognized as one of the most promising food derived compounds in fighting cancer. Sabinsa Corporation provides an extract of turmeric standardized to 95 percent curcuminoids, Curcumin C3 Complex(R). Over the past several years, numerous studies have been funded by the National Institutes of Health to investigate the role of curcumin and its derivatives in treatment of patients with cancer.
Additionally, M.D. Anderson Cancer Center is involved in pre-clinical and clinical research of the anti-cancer mechanism and application of curcuminoids in conditions including lung, breast, multiple myeloma, pancreatic, myelodysplatic syndrome, colon, prostate and head and neck cancers. For more information visit www.curcuminoids.com.

Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Sabinsa’s mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past nine years, Sabinsa has brought to market more than 50 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market.